TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
CADL

Candel Therapeutics Inc

Healthcare · Biotechnology

11.60$ +2.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement CADL
Line item 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% – –
5,285.6% – 185.6% 789.6% 77,354.8% – –
100.0% 100.0% 100.0% 100.0% -77,354.8% – –
5,285.6% 7,003.2% 12,142.4% 16,629.6% 79,051.6% – –
2,044.0% 4,144.8% 8,538.4% 11,248.0% 44,790.3% – –
7,329.6% 11,148.0% 20,680.8% 27,839.2% 123,841.9% – –
-7,229.6% -11,048.0% -20,580.8% -27,739.2% -123,841.9% – –
856.0% 88.8% 42.4% 1,366.4% 8,371.0% – –
-6,592.0% -14,144.0% -28,899.2% -15,035.2% -122,383.9% – –
-180.8% 3,595.2% 8,318.4% -12,742.4% – – –
-6,592.0% -14,144.0% -28,899.2% -15,035.2% -122,383.9% – –
-6,738.4% -10,476.0% -28,671.2% -13,046.4% -110,916.1% – –

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?